Overview

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Erlotinib Hydrochloride
Sunitinib